Wedbush Cuts Vigil Neuroscience (NASDAQ:VIGL) Price Target to $13.00

Vigil Neuroscience (NASDAQ:VIGL) had its price objective decreased by Wedbush from $24.00 to $13.00 in a report published on Friday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for Vigil Neuroscience’s FY2029 earnings at $1.40 EPS.

Other analysts have also recently issued research reports about the company. HC Wainwright dropped their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Friday. William Blair initiated coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. JMP Securities reissued a “market outperform” rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $16.25.

Vigil Neuroscience Trading Down 4.3 %

Vigil Neuroscience stock opened at $2.02 on Friday. The stock has a market cap of $82.58 million, a PE ratio of -0.98 and a beta of 1.82. The stock has a 50-day moving average price of $2.34 and a 200 day moving average price of $2.78. Vigil Neuroscience has a 52 week low of $1.49 and a 52 week high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). On average, equities analysts predict that Vigil Neuroscience will post -2.07 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC lifted its position in Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after acquiring an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new stake in Vigil Neuroscience during the 4th quarter worth approximately $83,000. Barclays PLC increased its holdings in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after purchasing an additional 19,436 shares during the last quarter. Northern Trust Corp increased its holdings in Vigil Neuroscience by 29.0% during the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after purchasing an additional 14,572 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Vigil Neuroscience by 243.8% during the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock worth $117,000 after purchasing an additional 49,000 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.